BeaconEquity.com - POZEN Inc. (POZN) Receives FDA Approval for Migraine Treatment
POZEN Inc. (POZN) Receives FDA Approval for Migraine Treatment POZEN Inc. was recently awarded a long-awaited approval from the U.S. Food and Drug Administration for its migraine drug, Treximet.
(EMAILWIRE.COM, April 21, 2008 ) BeaconEquity.com announces the publication of ‘POZEN Inc. (POZN) Receives FDA Approval for Migraine Treatment’
Investors can view all of the investment articles for free by visiting:
http://www.BeaconEquity.com - Click on News and Commentary
POZEN Inc. (POZN) Receives FDA Approval for Migraine Treatment
POZEN Inc. was recently awarded a long-awaited approval from the U.S. Food and Drug Administration for its migraine drug, Treximet. The company first requested approval from the administration in 2005, but was asked twice for more data; Treximet is being developed by POZEN, in collaboration with GlaxoSmithKline (GSK) for the treatment of acute migraine. Treximet is GSK’s proposed brand name for a proprietary single tablet containing sumatriptan succinate, a 5-HT 1B/1D agonist formulated with GSK’s RT Technology, and naproxen sodium, a nonsteroidal anti-inflammatory (NSAID) drug.
Compared with other drug-producing companies, POZEN provides a safer NSAID through its development of a proprietary product candidate, designated PN 400, for the treatment of conditions such as osteoarthritis in patients who are at risk for developing NSAID-associated gastric ulcers. The PN tablet is designed to contain an immediate release acid inhibitor with a delayed release NSAID in a single dosage form.
To read the entire article visit http://www.BeaconEquity.com – Click on News and Commentary
Join the fastest growing investor community at:
http://www.stockhideout.com
BeaconEquity.com’s Market News is one of the fastest growing small cap blogs in the investment community. Beacon is the authority on research in the small cap sector, and our analysts strive each day to find the stocks that are poised to be the biggest movers before the rest of the market is aware of them.
We encourage investors to subscribe to our FREE newsletter filled with daily trading ideas by visiting: http://www.BeaconEquity.com
BeaconEquity.com is one of the industry’s largest small cap research providers. Beacon strives to provide a balanced view of many promising small cap companies that would otherwise fall under the radar of the typical Wall Street investor. We provide investors with an excellent first step in their research and due diligence by providing daily trading ideas, and consolidating the publicly available information available on them. For more information on Beacon Research, please visit: http://www.BeaconEquity.com
Source: BeaconEquity.com
Beacon Equity Research
Jeff Bishop, (469)-252-3505
press@beaconequity.com
Investors can view all of the investment articles for free by visiting:
http://www.BeaconEquity.com - Click on News and Commentary
POZEN Inc. (POZN) Receives FDA Approval for Migraine Treatment
POZEN Inc. was recently awarded a long-awaited approval from the U.S. Food and Drug Administration for its migraine drug, Treximet. The company first requested approval from the administration in 2005, but was asked twice for more data; Treximet is being developed by POZEN, in collaboration with GlaxoSmithKline (GSK) for the treatment of acute migraine. Treximet is GSK’s proposed brand name for a proprietary single tablet containing sumatriptan succinate, a 5-HT 1B/1D agonist formulated with GSK’s RT Technology, and naproxen sodium, a nonsteroidal anti-inflammatory (NSAID) drug.
Compared with other drug-producing companies, POZEN provides a safer NSAID through its development of a proprietary product candidate, designated PN 400, for the treatment of conditions such as osteoarthritis in patients who are at risk for developing NSAID-associated gastric ulcers. The PN tablet is designed to contain an immediate release acid inhibitor with a delayed release NSAID in a single dosage form.
To read the entire article visit http://www.BeaconEquity.com – Click on News and Commentary
Join the fastest growing investor community at:
http://www.stockhideout.com
BeaconEquity.com’s Market News is one of the fastest growing small cap blogs in the investment community. Beacon is the authority on research in the small cap sector, and our analysts strive each day to find the stocks that are poised to be the biggest movers before the rest of the market is aware of them.
We encourage investors to subscribe to our FREE newsletter filled with daily trading ideas by visiting: http://www.BeaconEquity.com
BeaconEquity.com is one of the industry’s largest small cap research providers. Beacon strives to provide a balanced view of many promising small cap companies that would otherwise fall under the radar of the typical Wall Street investor. We provide investors with an excellent first step in their research and due diligence by providing daily trading ideas, and consolidating the publicly available information available on them. For more information on Beacon Research, please visit: http://www.BeaconEquity.com
Source: BeaconEquity.com
Beacon Equity Research
Jeff Bishop, (469)-252-3505
press@beaconequity.com
Press Release Keywords:
fda, migraine, migraine treatment, treximet, glaxosmithkline, acute migraine, stock market, small caps, micro caps, investing, headache, headache treatment, migraine medicine
fda, migraine, migraine treatment, treximet, glaxosmithkline, acute migraine, stock market, small caps, micro caps, investing, headache, headache treatment, migraine medicine
|
FREE Penny Stock Alerts!
Get Amazing Penny Stock ALERTS Totally FREE Click This Link NOW. GetRichPicks.com How to buy Penny Stocks Learn the Skills, Make the Trades, Earn a Fortune! 100% Free to try. Chartpoppers.com Stop Being Fooled By "Penny Stock Picks" Subscribe To The #1 Rated MicroCap Stock Newsletter. MicroCapster.com Analyst Penny Stock Picks Visit StockSource.us for explosive stock picks, free stock research and trading tools www.StockSource.us Your text Ads here! Ads are only $575 per month. Ads are placed same day. Contac Us Emailwire.com/contact.php |